First Trust Advisors’s Relay Therapeutics RLAY Stock Holding History

First Trust Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-89,949	Closed	-$371K	–	2607
2024 Q4	$371K	Buy	+89,949	New	+$489K	﹤0.01%	2328
2024 Q2	–	Sell	-118,644	Closed	-$985K	–	2407
2024 Q1	$985K	Buy	+118,644	New	+$1.16M	﹤0.01%	1987
2023 Q1	–	Sell	-13,234	Closed	-$198K	–	2452
2022 Q4	$198K	Sell	13,234 -54,163	-80%	-$1.04M	﹤0.01%	2375
2022 Q3	$1.51M	Buy	67,397 +53,014	+369%	+$1.16M	﹤0.01%	1827
2022 Q2	$241K	Buy	+14,383	New	+$308K	﹤0.01%	2352

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

First Trust Advisors's RLAY Position: Q1 2025 in Review

First Trust Advisors sold out of Relay Therapeutics (RLAY) in Q1 2025, closing a stake of 89,949 shares — an estimated $371K sold.

First Trust Advisors first reported a position in RLAY in Q2 2022 and held it in 5 quarters. The position peaked at $1.51M in Q3 2022. 207 funds tracked by Wall St. Rank hold RLAY as of Q1 2025.

First Trust Advisors reported no remaining Relay Therapeutics position as of Q1 2025 after selling out during the quarter.
First Trust Advisors sold 89,949 Relay Therapeutics shares in Q1 2025, an estimated $371K.
First Trust Advisors first reported a position in Relay Therapeutics in Q2 2022 and held it in 5 quarters.
First Trust Advisors's Relay Therapeutics position peaked at $1.51M in Q3 2022.
207 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2025.

Based on First Trust Advisors's 13F filing for Q1 2025, filed 14 May 2025.